VRTX · Earnings call · 2026Q3T · Full report

ALYFTREK Market Adoption

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 26 · Surprise 24

ALYFTREK growth is being driven by patients switching from Trikafta and by new patients with rare mutations, with more than 18,000 patients benefiting worldwide. Reimbursement was in place in 31 countries outside the U.S., and management cited new reimbursement agreements and rare-mutation indications as key growth drivers. Additional opportunities include expansion into younger age groups and additional geographies.

Key facts

• Vertex reported 2026 year-to-date ALYFTREK sales in the U.S. had surpassed $1 billion.
• More than 75% of ALYFTREK-treated trial patients ages 12 and older achieved sweat chloride levels in the range of CF carriers.
• ALYFTREK is once-daily and can treat up to 95% of people with CF.
• Vertex received reimbursement for ALYFTREK in 31 countries outside the U.S.
• Vertex received additional ALYFTREK reimbursement agreements outside the U.S. in Q3 2026; growth was also driven by rare-mutation indications and new patients.
• Vertex reported more than 18,000 patients benefiting from ALYFTREK worldwide.